Compare SACH & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | IOBT |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 57.2M |
| IPO Year | 2017 | 2021 |
| Metric | SACH | IOBT |
|---|---|---|
| Price | $1.05 | $0.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.00 | ★ $3.50 |
| AVG Volume (30 Days) | 150.4K | ★ 907.6K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | ★ 19.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,906,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.32 |
| 52 Week High | $1.65 | $2.79 |
| Indicator | SACH | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 43.00 |
| Support Level | $0.96 | $0.69 |
| Resistance Level | $1.08 | $0.83 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 53.85 | 25.32 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.